Cipla gets FDA form 483; concerns over Indore plant
Indian drug maker Cipla has been served nine observations by the US FDA for its Indore-based manufacturing unit as part of an inspection that was conducted during July and August this year. The observations is a summary note of issues noticed by the FDA officials and needs corrections.
Other Daily Videos
Budget 2024: ET Now explains key parameters you need to keep an eye on
IMF raises India's FY25 GDP growth forecast to 6.5%
Cross-hospital cashless treatment is a major move: New India Assurance CMD
Zee Ent moves NCLT after Sony terminates merger deal
ED conducts searches at Essel Group office in Mumbai, probes employees
